Pioneering Next Generation HDAC6i’s to advance life-changing disease cures for CMT patients and other peripheral neuropathies.
Miralinc was founded with the initial support of the HNF.
Histone deacetylase subtype 6 (HDAC6) is the therapeutic target with strong preclinical validation from academic research in animal models of peripheral neuropathies. HNF has supported a decade of research in this class of drugs with academic TRIAD partners.
Learn more about
Learn more on this topic
Latest News and Related Blog Posts
No Results Found
The page you requested could not be found. Try refining your search, or use the navigation above to locate the post.